Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less "go" and more "stop" from the motor striatum for robust therapeutic effects.
about
Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less "go" and more "stop" from the motor striatum for robust therapeutic effects.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Mechanism of action of vesicul ...... or robust therapeutic effects.
@en
Mechanism of action of vesicular monoamine transporter 2
@nl
type
label
Mechanism of action of vesicul ...... or robust therapeutic effects.
@en
Mechanism of action of vesicular monoamine transporter 2
@nl
prefLabel
Mechanism of action of vesicul ...... or robust therapeutic effects.
@en
Mechanism of action of vesicular monoamine transporter 2
@nl
P2860
P1433
P1476
Mechanism of action of vesicul ...... or robust therapeutic effects.
@en
P2093
Stephen M Stahl
P2860
P356
10.1017/S1092852917000621
P577
2017-12-18T00:00:00Z